Ono Pharmaceutical, Medarex to Collaborate in Research on Fully Human Antibody.Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, Mar 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Ono Pharmaceutical and Medarex have signed a collaborative agreement to research and develop a fully human anti-SDF-1 antibody. Under this collaboration Working together on a project. See collaborative software. , the two companies aim to commercialize a fully human antibody. They will share the costs and responsibilities of research and product development up to the completion of a phase II clinical study. After establishing the proof of concept (demonstration of efficacy and safety in humans), the two companies will continue development separately: Medarex in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. and Ono Pharmaceutical in all areas outside North America. Currently, the two companies are creating compound candidates using Medarex's UltiMAb Human Antibody Development System. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion